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ScienceDirectFibrosis, the excessive accumulation of extracellular matrix, is
a major global healthcare burden. Despite major advances in
our understanding of the mechanisms regulating fibrosis,
treatment options for patients with fibrosis remain very limited.
However, recent developments in the rapidly evolving field of
single-cell transcriptomics are enabling the interrogation of
individual pathogenic cell populations in the context of fibrosis
at unprecedented resolution. In this review, we will discuss how
single-cell transcriptomics is driving this step change in our
understanding of fibrotic disease pathogenesis, and how these
cutting-edge approaches should accelerate the precise
identification of novel, relevant and potentially druggable
therapeutic targets to treat patients with fibrosis.
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Introduction
Fibrosis, characterised by the excessive accumulation of
extracellular matrix, contributes to a high level of mor-
bidity and mortality worldwide [1–3]. Despite advances
in our understanding of the cellular and molecular mech-
anisms regulating this process, the therapeutic options
available to treat fibrosis remain very limited [4–7]. How-
ever, recent advances in single-cell omic technologies,
such as single-cell RNA sequencing (scRNA-seq), are
allowing the interrogation of individual pathogenic cell
populations at unprecedented resolution (Figure 1). The
identification of novel cell types and states afforded by
scRNA-seq analysis not only greatly advances our under-
standing of the mechanisms underlying disease, but also
accelerates the precise identification of new, highly rele-
vant and potentially druggable therapeutic targets [8]. In
this review, we will discuss how single-cell transcrip-
tomics is driving a step change in our understanding of
fibrotic disease pathogenesis.www.sciencedirect.com Lung
The initiation and progression of lung fibrosis is driven by
a complex interplay between multiple cell lineages.
Given the importance of macrophages in regulating
numerous pathological processes including organ fibrosis
[9], and the fact that they represent a diverse and plastic
population, scRNA-seq is particularly well-suited to the
further investigation of this cell type in the context of
lung fibrosis. Chakarov et al. performed an elegant study
demonstrating the value of scRNA-seq in the investiga-
tion of macrophage heterogeneity. Interrogating intersti-
tial macrophages (IM) in healthy mouse lung they
identified two distinct populations, classified as
Lyve1loMHCIIhi and Lyve1hiMHCIIlo IM with differing
transcriptional profiles [10]. Complementary fate-map-
ping models identified these IM populations as two
separate lineages of monocyte-derived cells which reside
within different anatomical niches in the lung and have
distinct functions. Interestingly, this dichotomy in IM
was conserved across multiple mouse tissues including
heart, fat and dermis as well as human lung. Selective
ablation of Lyve1hiMHCIIlo IM exacerbated lung fibro-
sis, highlighting their critical role during lung injury, and
identifying these cells as a potential antifibrotic target
[10]. Similarly, using scRNA-seq in a murine model of
pulmonary fibrosis, Aran et al. identified a profibrogenic
transitional macrophage population that is intermediary
between monocyte-derived and alveolar macrophages,
that localise to the fibrotic niche [11]. Orthologs of
genes expressed by this transitional population were
shown to be upregulated in samples from patients with
idiopathic pulmonary fibrosis highlighting conserved
fibrogenic pathways across species. Furthermore, these
pro-fibrotic transitional macrophages were shown to reg-
ulate fibroblast biology via secretion of PDGF-AA, poten-
tially offering insight into how nintedanib, a PDGF
receptor inhibitor and one of the few therapies currently
approved to treat lung fibrosis, mediates its effects [12].
During lung fibrosis mesenchymal cells are responsible
for extracellular matrix production that ultimately leads to
architectural distortion and decline in lung function.
ScRNA-seq has been used to characterise lung mesen-
chymal cell heterogeneity in both healthy and fibrotic
mouse lung [13–15]. In conjunction with transgenic
reporter lines this has led to the generation of a spatial
and transcriptional map of healthy lung mesenchyme
uncovering distinct populations including mesenchymal
alveolar niche cells (MANC) – responsible for supporting
alveolar growth and regeneration, and myofibroblast pro-
genitor (AMP) cells – the major contributors to myofi-
broblasts following injury [14]. Studies assessingCurrent Opinion in Pharmacology 2019, 49:71–75
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Resolving cellular state, subpopulations, differentiation dynamics and inter-cellular interactions using single-cell transcriptomic approaches.mesenchymal cells in bleomycin-induced fibrotic mouse
lung have uncovered extensive cellular heterogeneity,
with slightly differing conclusions. These may be sec-
ondary to differences in duration of lung injury, cell
isolation techniques and the analysis approaches used
[13,15]. Xie et al., provide a purely computational analysis
of mesenchymal cell heterogeneity in healthy and fibrotic
lung disease, identifying seven distinct populations of
mesenchymal cell in fibrotic mouse lung, including an
injury-specific PDGFRbhi population [15]. In contrast,
Peyser et al. conclude that activated fibroblasts are not
uniquely defined, but instead display a similar, albeit
amplified gene expression pattern to control cells [13].
Interestingly, both studies cast doubt on the use of Acta2
as a marker to define disease-associated fibroblasts.
Extensive scRNA-seq studies have also been performed
in human lung. Reyfman et al. provided the first single cell
atlas of human pulmonary fibrosis, analysing over
70 000 cells from eight patients with pulmonary fibrosis
of varying aetiologies and eight uninjured donor lung
samples [16]. By analysing each subject separately, asCurrent Opinion in Pharmacology 2019, 49:71–75 well as performing an integrated analysis of all patients
combined, the authors were able to comment on patient-
specific populations which were lost in the integrated
analysis, highlighting the important point that subtle
inter-patient differences can be lost when only assessing
integrated datasets. Furthermore, they characterised an
injury-specific population of profibrotic monocyte-
derived alveolar macrophages which had previously been
identified in mice [9]. This study also highlighted that
scRNA-seq from lung tissue obtained at time of bron-
choscopy is technically possible, suggesting that scRNA-
seq approaches may in time have applications in the
diagnosis and monitoring of treatment responses in pul-
monary fibrosis [16].
In recent years, increasing evidence suggests that epithe-
lial cells play an important regulatory role in lung fibro-
genesis [17]. To characterise the changes in epithelial
heterogeneity in human fibrotic lung Xu et al. performed
scRNA-seq on three control and six idiopathic pulmonary
fibrosis (IPF) patient samples. They uncovered signifi-
cant changes in the lung epithelia including thewww.sciencedirect.com
Unravelling fibrosis using single cell genomics Dobie and Henderson 73identification of an injury-specific population of atypical
‘indeterminate’ cells that did not express signature genes
associated with any known lung epithelial subtype. This
population generally expressed AT2 cell-associated mar-
kers, however gene set enrichment analysis uncovered
unique predicted functions including ‘activation of
myofibroblasts’ [18].
Liver
To date scRNA-seq in the liver has focussed predomi-
nantly on characterising the cellular landscape during
liver homeostasis [19,20,21,22,23]. Generation of
these reference maps in healthy, homeostatic liver are
a critical platform from which to develop our understand-
ing of liver disease pathogenesis.
ScRNA-seq permits interrogation of subtle differences in
gene expression within a given cell lineage allowing high
resolution mapping of populations to their topographical
location. In an elegant study, Halpern et al. used scRNA-
seq along with spatially mapped landmark genes to anno-
tate zonation of distinct hepatocyte subpopulations across
the mouse liver lobule. Challenging the traditional binary
classification of the liver into periportal and pericentral
zones they found that the intermediate lobule is likely to
have specialised functions [21]. These key findings
have since been confirmed by other groups in mouse
and human liver [19,23]. In a further study, Halpern
et al. harnessed the spatial information gathered from
their previous hepatocyte zonation work [21], and cou-
pled this with a novel technique called paired-cell
sequencing [22]. This technique sequences mRNA from
pairs of attached cells, leveraging the gene expression
profile of one cell lineage within the pair to allow infer-
ence of the other cell’s spatial coordinates. The authors
used this approach to characterise endothelial cell zona-
tion within the liver [22]. Many pathological conditions
in the liver demonstrate zonality and are spatially hetero-
geneous, however the role of zonation in disease initiation
and progression remains largely unknown [24]. It is likely
that in the coming years single-cell transcriptomics will
begin to shed light on the role of cellular zonation in liver
disease.
Despite the rapid progress in our understanding of the
mechanisms underlying liver fibrogenesis accrued using
rodent models, a significant ‘translational gap’ remains
between potential therapeutic targets and effective ther-
apies [4,25], and as such there is a real drive to gain a
better understanding of the human liver cellular land-
scape in health and disease. To date there have been two
comprehensive scRNA-seq studies of human liver
[19,20]. MacParland et al. interrogated the transcrip-
tome of over 8000 parenchymal and non-parenchymal
cells obtained from five healthy human livers generating a
cell atlas comprising 20 discrete cellular subpopulations
derived from the main hepatic cell lineages [19]. Theywww.sciencedirect.com describe macrophage heterogeneity in the human liver,
identifying two distinct populations—recently recruited
pro-inflammatory macrophages and resident Kupffer cells
which have a more immunoregulatory phenotype. Similar
macrophage subpopulations have since been described in
other human studies [20]. As a cautionary note, McPar-
land et al. highlight that tissue preparation methodologies
likely have a significant impact on the ability to transcrip-
tionally profile all hepatic cell populations, with hepato-
cytes being particularly susceptible to dissociation effects
[19]. In a second human liver scRNA-seq study, Aizar-
ani et al. have used an alternative approach (diffusion
pseudo-time (dpt)) to the previous studies in mouse to
classify functional zonation of hepatocytes and endothe-
lial cells in human liver. Interestingly, in a comparison of
mouse [21,22] and human data they discovered only
limited evolutionary conservation of gene expression,
again highlighting the important differences between
mouse and human biology. Focussed analysis of the
EpCAM+ cellular compartment lead to classification of
a potential human liver progenitor cell type with the
capacity to form organoids [20].
ScRNA-seq experiments on fibrotic liver have focussed
on interrogating hepatic stellate cells (HSC)/myofibro-
blasts and immune cells. Currently HSC are thought to be
the major source of myofibroblasts during liver fibrosis,
independent of aetiology [26,27], however it must be
noted that these data are derived from mouse models
of liver fibrosis and not human studies. ScRNA-seq stud-
ies in a rodent model of liver fibrosis have shown that
myofibroblasts are a heterogeneous population in the
fibrotic liver [28]. While activated myofibroblasts could
be identified by the universal activation marker S100a6,
as well as upregulation of fibrillar collagens, expression of
certain chemokines was restricted to specific subpopula-
tions [28]. Non-alcoholic fatty liver disease (NAFLD) is
the most prevalent liver disease worldwide [29] and as a
result there is a drive to gain a deeper understanding of
the mechanisms regulating this disease. Characterisation
of myeloid cell subsets in the liver and bone marrow from
high-fat, high-sugar, high-cholesterol ‘western diet’—fed
mice revealed an adaptation to a specific inflammatory
phenotype during NAFLD progression, characterised by
downregulation of inflammatory calprotectin (S100a8/a9)
in macrophage and dendritic cell subsets with effects on
inflammatory polarisation and modulation of responses to
acute sterile liver injury [30].
Kidney
Since the emergence of scRNA-seq there have been a
number of publications investigating the cellular compo-
sition of the kidney in development, homeostasis, cancer
and fibrosis [31–36]. One of the first applications of
scRNA-seq in the kidney elegantly highlights the power
of this technique in the investigation of disease patho-
genesis. Park et al. generated a single-cell atlas of healthyCurrent Opinion in Pharmacology 2019, 49:71–75
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seq kidney data from rat, microarray data from human
immune cells and transgenic mouse reporter lines, they
were able to provide molecular definitions for 18 previ-
ously defined kidney populations, as well as three novel
cell types including a transitional population of cells with
an expression profile likened to both principal cells (PC)
and intercalated cells (IC) of the collecting duct [32].
Lineage tracing experiments demonstrated plasticity
between PC and IC through this newly identified transi-
tional population. Interestingly, the authors demon-
strated that Notch-mediated IC to PC transition is a
possible cause of metabolic acidosis in mouse models
and patients with chronic kidney disease [32].
Fibrosis is the final common pathway of virtually all types
of chronic kidney injury, and while it is accepted that
myofibroblasts are the scar-producing cells in the kidney,
their cellular origin is still a matter of debate [37]. Using a
parabiosis model, Kramann et al. demonstrated that only a
small percentage of myofibroblasts are derived from cir-
culating cells. ScRNA-seq characterisation of this popu-
lation (PDGFRb+CD45+) as well as resident myofibro-
blasts (PDGFRb+CD45) confirmed these findings,
identifying two distinct populations of cells. While the
resident myofibroblast population was largely associated
with matrix production, myofibroblasts derived from the
circulation were shown to have a monocyte-like pheno-
type associated with immune response mechanisms [36].
Despite the immense progress that has been made with
regard to understanding disease pathogenesis using
scRNA-seq, there are number of factors to consider when
using this technique. These include the underrepresen-
tation of certain cell types due to cell fragility and/or
difficulty in liberating specific cell types during tissue
dissociation, the introduction of cell stress artefacts sec-
ondary to prolonged isolation protocols, and the inability
to generate high quality whole cell scRNA-seq data from
frozen, archived tissue. Single nuclei sequencing
(snRNA-seq) is an emerging complementary approach
that may help address a number of these issues, as it
allows an unbiased assessment of nuclei from all cell
lineages present within a tissue, and importantly unlocks
analysis of biobanked frozen tissues. A recent study of
mouse kidney has compared a number of snRNA-seq
platforms with standard scRNA-seq workflows and found
that snRNA-seq approaches result in detection of fewer
stress related genes and increased detection of specific
cell types including podocytes, endothelial cells, and
intercalated cells [38]. Furthermore, this study found
that snRNA-seq of fibrotic kidney uncovered novel and
rare populations, resulting in increased resolution of the
cellular composition present during kidney fibrogenesis.
Taking into account the advantages of snRNA-seq out-
lined in this study, along with the availability of frozen
archived fibrotic human tissue, it is likely that the use ofCurrent Opinion in Pharmacology 2019, 49:71–75 snRNA-seq will increase in the coming years, further
expanding our understanding of the mechanisms under-
lying fibrotic disease.
Conclusions
The rapidly evolving field of single-cell transcriptomics
has already led to important, new discoveries in the
context of tissue fibrosis. Furthermore, developing tech-
nologies such as single-cell epigenomics, single-cell pro-
teomics, and spatial transcriptomics will allow the
research community to further define the cellular and
molecular mechanisms regulating fibrosis at even higher
resolution. These cutting-edge approaches will advance
our understanding of how the fibrotic niche operates
across the different forms of tissue fibrosis, and should
generate rational and potentially druggable therapeutic
targets to treat patients with fibrosis.
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